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Although singlet oxygen (
1O2) has long been proposed as the primary reactive oxygen species in photodynamic therapy (PDT), it has
only recently been possible to detect it in biological systems by its luminescence at 1270nm. Having previously demonstrated this in
vitro and in vivo, we showed that cell survival was strongly correlated to the
1O2 luminescence in cell suspensions over a wide range of
treatment parameters. Here, we extend this to test the hypothesis that the photobiological response in vivo is also correlated with
1O2 generation, independent of individual treatment parameters. The normal skin of SKH1-HR hairless mice was sensitised with 20%
amino-levulinic acid-induced protoporophyrin IX and exposed to 5, 11, 22 or 50Jcm
 2 of pulsed 523nm light at 50mWcm
 2,o rt o
50Jcm
 2 at 15 or 150mWcm
 2.
1O2 luminescence was measured during treatment and the photodynamic response of the skin
was scored daily for 2 weeks after treatment. As observed by other authors, a strong irradiance dependence of the PDT effect was
observed. However, in all cases the responses increased with the
1O2 luminescence, independent of the irradiance, demonstrating for
the first time in vivo an unequivocal mechanistic link between
1O2 generation and photobiological response.
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Photodynamic therapy (PDT) is an emerging therapy for the
treatment of solid tumours and some nonmalignant conditions
(Dougherty et al, 1998; Stewart et al, 1998). The therapy involves
the activation of light-sensitive drugs with a laser or other light
source to generate reactive oxygen species (ROS). For most
clinically used photosensitisers, the most important ROS is
believed to be singlet oxygen (
1O2 (
1Dg)) (Weishaupt et al, 1976).
The action of
1O2 results in modification or destruction of the
target tissue and subsequent clinical effects (Schweitzer and
Schmidt, 2003).
Since PDT involves three interdependent and dynamic treat-
ment factors (i.e. light, photosensitiser and oxygen), complete and
accurate dosimetry is a difficult problem and is the focus of
ongoing research by several groups. Several techniques have been
proposed (Wilson et al, 1997a), such as ‘explicit dosimetry’, in
which the quantities of light, drug and oxygen are continuously
monitored during treatment. Alternatively, ‘implicit dosimetry’
utilises a surrogate for biological damage, such as the photode-
gradation of the photosensitiser (fluorescence) during treatment to
predict treatment outcome (Wilson et al, 1997a; Dysart et al, 2002).
The focus of the present work is ‘direct dosimetry’, which entails
direct measurement of
1O2 during treatment.
In PDT,
1O2 is generated by the following type-II pathway
(Patterson et al, 1990):
S0 þ hu ! S1
S1 ! T1
T1 þ 3O2 ! S0 þ 1O2
ðAÞ
where S0,S 1 and T1 are the ground singlet, first excited singlet and
first excited triplet states of the photosensitiser, respectively and
3O2 and
1O2 are the ground triplet and first excited singlet states of
molecular oxygen, respectively. Once generated,
1O2 may undergo
radiative decay at 1270nm with a low probability. This lumine-
scence is routinely measurable in solution (Krasnovsky, 1998), but
in vitro and in vivo the lifetime of
1O2 drops dramatically, from
approximately 3ms to around 100ns (Moan and Berg, 1991;
Schweitzer and Schmidt, 2003) because of the rapid reaction of
1O2
with surrounding biomolecules. Likewise, the probability of
radiative decay drops, such that measurement of this luminescence
in biological media has traditionally not been feasible due to
limited detector sensitivity and/or temporal response. Never-
theless, there has been significant interest in doing this, both for
basic photobiological research and as a potential PDT dosimetry
tool (Parker, 1987; Gorman and Rodgers, 1992).
In 2002, we showed for the first time that this is now possible
using a novel near-infrared (NIR)-sensitive photomultiplier tube
(PMT) (Niedre et al, 2002b). Specifically, we measured
1O2
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sluminescence in vitro from leukaemia cells and in vivo in normal
liver and skin of Wistar rats, sensitised with aluminium
tetrasulphonated phthalocyanine (AlS4Pc). Subsequently, Hirano
et al (2002) also showed that this was possible in vivo in implanted
murine tumours sensitised with ATX-S10 using the same PMT.
More recently, we published a set of experiments that showed
that
1O2 luminescence was a useful PDT dose metric in vitro
(Niedre et al, 2002a, 2003). Specifically, this demonstrated that the
killing of OCI-AML5 leukaemia cells treated with aminolevulinic
acid (ALA)-induced protoporphyrin IX (PpIX) PDT correlated very
strongly with the
1O2 luminescence measured during treatment,
regardless of initial photosensitiser concentration, irradiance or
molecular oxygen concentration. These experiments differed from
our initial feasibility study in that the light and photosensitiser
conditions were typical of clinical PDT treatments (as opposed to
being optimised for generation of
1O2) and, hence, substantial
technical upgrades were required to the detection system.
Following this encouraging first step, we report here a set of
experiments that extend this concept to an in vivo model,
specifically the normal skin of hairless mice sensitised with ALA-
PpIX. For this, we used an available green (523nm) light source,
for which the
1O2 generation and PDT effect were both confined to
relatively superficial tissue. This model is based on studies
conducted by Robinson et al (1998) that attempted to correlate
PpIX photobleaching with the observed skin response measured
daily for 2 weeks following treatment. Here, we observed (as did
Robinson et al) a strong irradiance dependence of the response,
despite identical ALA concentrations and total treatment fluence.
We show that the
1O2 luminescence generated during treatment
correlates well with the observed skin response in all cases,
regardless of the treatment fluence or irradiance. To our know-
ledge, this is the first time that such a correlation has been
demonstrated in vivo.
As will be discussed, these data support the hypothesis that
1O2
is the primary ROS involved in PDT in vivo. They are also
encouraging for the development of
1O2 luminescence-based
preclinical and/or clinical PDT dosimetry systems.
MATERIALS AND METHODS
Theory
As described in detail previously (Niedre et al, 2002b), the local
1O2 concentration as a function of time generated by a short laser
pulse is given by:
½1O2 ðtÞ¼Ns½S0 FD
tD
tT   tD
½expð t=tTÞ expð t=tDÞ  ðBÞ
where N is the number of photons per cm
2 in the excitation pulse
incident on the sample, s is the photosensitiser ground state
absorption cross-section (cm
2), [S0] is the concentration of the
photosensitiser ground state, FD is the quantum yield of
1O2, and
tT and tD are the photosensitiser triplet-state lifetime and
1O2
lifetime, respectively.
The total number of photons emitted in the radiative decay of
1O2 at 1270nm is given by
L1270ðtÞ¼
½1O2 ðtÞ
tR
ðCÞ
where tR is the radiative lifetime of
1O2 in the specific
environment. Equation (C) can be integrated over time to give
the total number of photons emitted after excitation by a single
laser pulse as Z
L1270ðtÞdt ¼
Ns½S0 FDtD
tR
ðDÞ
Hence, the concentration of
1O2 generated in a sample is directly
proportional to the total emitted luminescence.
We approximate integral (D) experimentally by counting the
total luminescence in the interval between 2 and 90ms following
the laser pulse and subtracting background contributions. Since
the laser was operating at 10kHz, by counting in this interval the
system was actively measuring 88% of the time. As in our earlier
work, the contributions from the first 2ms were rejected due to
strong fluorescence contributions to the signal from the photo-
sensitiser and some optical elements. Since the kinetics of the
1O2
luminescence were determined by Equation (B), we could expect
that, despite the extremely short tD in tissue, the
1O2 full-time
curve would last several tT. Our previous estimates for tT in tissue
were between 25 and 30ms (Niedre et al, 2002b), and in the present
experiments were confirmed to be 30 to 40ms (data not shown).
However, even if tT was very long (e.g. due to very low pO2) the
loss of counts would be small (i.e. o12%) due to the high duty
cycle of the system.
Apparatus
The apparatus used to measure
1O2 luminescence in vivo is shown
in Figure 1. This system has been described in detail elsewhere
(Niedre et al, 2003), with modifications made for the current
experiments as follows: (i) The NIR PMT (R5509-14, Hamamatsu
Corp., Bridgewater, NJ, USA) was mounted vertically, so that the
detector and collection optics were above the animals. As before,
the operating voltage of the PMT was set to  1500V using a high
voltage power supply (model SR445, Stanford Research Systems,
Sunnyvale, CA, USA); (ii) a small, 4mm 4mm silver-coated
prism (01-PRS-411, Melles Griot Inc., Nepean, ON, Canada) was
mounted directly in front of the silicon long-pass filter and used to
redirect the laser beam 901 towards the skin surface. This allowed
illumination of the skin while maintaining close positioning
between it and the detection optics and to give a high numerical
aperture for maximum light collection, and (iii) the multichannel
scalar was replaced with a high-speed multiscalar module (Becker
and Hickl MSA-300, Boston Electronics, Brookline, MA, USA),
which allowed us to operate the laser at 10kHz without loss of
signal due to speed limitations of the electronics.
As with our earlier studies (Niedre et al, 2002a, 2003), the laser
was a 523nm diode-pumped, Q-switched frequency-doubled
Nd:YLF (QG-523-500; Crystalaser Inc., Reno, NV, USA) with a
pulse width of B10ns. The irradiance at the skin was controlled
using a set of neutral density filters (FW2AND, Thor Labs Inc.,
PMT
Laser
Pre-
Amp PC Photon 
counter
High-voltage 
power supply
Bi-convex
f = 2′′, D = 2′′ lenses
1000 nm, D = 2′′ LP filter
5 position 
filter wheel
Silver-coated
prism
Figure 1 Schematic of the experimental system.
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sNewton, NJ, USA). As also noted in our earlier studies (Niedre et al,
2002b, 2003), there are other potential sources of luminescence in
the NIR range besides
1O2 luminescence, including detector dark
counts, luminescence from optical components, tissue auto-
fluorescence, and photosensitiser fluorescence and phosphore-
scence. Spectral discrimination of the detected light was, therefore,
achieved using a set of five narrow-band filters centred at 1212,
1240, 1272, 1304 and 1332nm (OD3 blocking, 20nm FWHM;
Omega Optical, Brattleboro, VT, USA) mounted on a motorised
filter wheel in front of the detector. For simplicity, these will be
referred to as the 1210, 1240, 1270, 1300 and 1330nm filters. The
system was automated with a personal computer so that the filter
sequence could be customised between experiments.
The mice were placed on a translatable X–Y–Z platform and the
skin was kept flat with small clamping arms during treatment. A
pair of small 1mW, 635nm lasers (CPS180; Thor Labs) was aligned
so as to intersect at the focal point of the collection optics. This
ensured that the treated spots were positioned so that the
illumination/collection geometry was consistent between experi-
ments. These lasers were shut off immediately after positioning the
animal and were on for only a few seconds.
Photodynamic therapy
A total of 39 female hairless mice were used (SKH1-HR, Charles
River Laboratories Inc., Wilmington, MA, USA), 7–12 weeks old.
These were maintained on a low-fluorescence chow diet for at least
2 weeks prior to treatment. They were sensitised 4h prior to
irradiation with a distilled water solution of 20% ALA (Sigma
Chemical Co., St Louis, MO, USA) with 2 M NaOH (Sigma) added
to raise the pH to 4 and 5% carboxymethyl cellulose (Sigma) added
to increase the viscosity. This solution was applied topically to two
spots (each B2 2cm
2) on the dorsal skin and covered with a
transparent adhesive dressing (Tegaderm 1626W, 3M Health Care,
St Paul, MN, USA). Two PDT treatments were performed on each
mouse in order to minimise the total number of animals used in
the study. These treatments were chosen randomly from the set
described below, so that the left side and right side generally
received different treatments. Immediately before the application
of ALA, the stratum corneum was stripped using medical tape to
facilitate diffusion of the ALA into the epidermis.
Since we had not shown previously that it was possible to
measure
1O2 luminescence in vivo specifically with ALA-PpIX, a
pilot study was conducted on a group of nine animals. The first
three were sensitised with ALA-PpIX as above, and irradiated with
50mWcm
 2 treatment light, a second set of three were
unsensitised controls and the final three were sensitised with
ALA-PpIX and euthanised by intracardiac injection of T-61
(Houchst Roussel Vet, Whitby, SK, Canada) 5min prior to
irradiation. The last set allowed us to check the effect of hypoxia
on the
1O2 signal.
After this initial investigation, full treatments were performed to
investigate the relationship between
1O2 luminescence and PDT
treatment response. The treatments were repeated six times in all
cases and, as summarised in Table 1, were as follows: (i) a
irradiance of either 15, 50 or 150mWcm
 2 was delivered to a
constant total fluence of 50Jcm
 2; (ii) a total fluence of either 5.5,
11, or 22Jcm
 2 was delivered at a constant irradiance of
50mWcm
 2; (iii) unsensitised control animals were irradiated
with 50Jcm
 2 at either 15, 50 or 150mWcm
 2 and; (iv) control
animals were sensitised but not irradiated. In cases (i–iii) the
irradiated spot was 7 7mm
2. Since the experiments were
performed over a period of several months, the order in which
they were performed was randomised in order to minimise any
bias, for example in the system sensitivity. For practical reasons,
these were not exactly the same treatments performed by Robinson
et al (1998), but are all in the same range of light and drug
parameters used.
Skin scoring
Following treatment, the irradiated spot was marked and the
animals were housed in darkness for 24h and then observed daily
for 2 weeks. On each day, an observer, blinded to the PDT
treatment, assigned a numbered skin response score for each
treated spot in the range 0–6, as summarised in Table 2.
Photographs of the treated spots were taken with a calibrated
colour card each day to document the response. All experiments
were performed in compliance with the guidelines of the Ontario
Cancer Institute Animal Care Committee.
Singlet oxygen measurement and data analysis
The detection wavelength was selected by positioning the
appropriate band-pass filter in front of the PMT. In these
experiments, the system was set up to acquire for 345000 laser
pulses per filter. This took 37s, including filter wheel motion and
data processing.
Near-infrared luminescence measurements were made during all
of the above experiments, including unsensitised controls. All
signals were corrected for minor differences in the transmission
characteristics of the optics at each wavelength. For the pilot
group, measurements were made at all five wavelengths, giving
more spectral information. For the animals in which full
treatments were given, only three wavelengths (1240, 1270 and
1300nm) were used in order to reduce the acquisition time, which
totaled 111s.
The measured spectra in the sensitised animals were corrected
for background contributions by subtracting the mean spectrum
from the control animals irradiated at the same irradiance. The
1O2
luminescence signal was then calculated as the photon counts at
1270nm minus the average of the counts at 1240 and 1300nm (i.e.
the linearly interpolated background at 1270nm). The resulting
value was then multiplied by 3, since the system acquired at each
wavelength only 1/3 of the time.
Table 1 Summary of the PDT treatments, repeated 6 times in all cases
Fluence rate
(mWcm
 2)
Fluence
(Jcm
 2)
Treatment
time (s)
ALA
concentration
150 50 333 20%
50 50 1000 20%
15 50 3333 20%
50 22 440 20%
50 11 220 20%
50 5.5 110 20%
15, 50, 150 50 333, 1000, 3333 0%
0 0 0 20%
Table 2 Visual skin-response scoring system (Robinson et al, 1998)
Score Observation
0 No observable effect
1 Mild erythema
2 Moderate erythema
3 Strong erythema
4 Dry desquamation
5 Thin scab formation
6 Thick scab formation
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sRESULTS
Figure 2 shows typical, 5-wavelength spectra measured in the pilot
group, including the sensitised, unsensitised and euthanised
animals (50mWcm
 2). As expected for
1O2 luminescence, a clear
1270nm peak was observed for the live sensitised animals. As will
be demonstrated below, significant variability was observed both
in terms of
1O2 generation and treatment response, even between
animals receiving PDT under the same conditions. For this reason,
representative data from a single sensitised animal are shown, as
opposed to the average of the
1O2 luminescence observed from all
of the live sensitised animals. A small but still significant peak at
1270nm was observed in the unsensitised control animals, most
likely due to
1O2 generated from naturally occurring porphyrins in
the skin. No peak was observed at 1270nm in the sensitised but
euthanised animals, confirming the oxygen dependence of the
signal. Hence, the system was capable of measuring
1O2
luminescence in this in vivo model.
Figure 3 shows the average, cumulative
1O2 luminescence for
sensitised animals treated with 15, 50 and 150mWcm
 2 up to a
total fluence of 50Jcm
 2, after subtracting the mean control
(unsensitised) spectra at the same irradiances. The total
1O2
luminescence decreased with increasing irradiance. This trend was
statistically significant between the three groups: specifically, one-
tailed Student’s t-tests yielded P¼0.005 comparing the 15 and
50mWcm
 2 treatments and P¼0.014 between the 50 and
150mWcm
 2 treatments. Note that the error bars in Figure 3
represent the standard deviation between the six animals in each
experiment. The error due to photon counting statistics was
negligible compared to this systematic variability. The relevance of
this observation is discussed below.
Similar curves were measured for all other treatment groups.
Figure 4 summarises the mean total
1O2 luminescence observed in
each group. As would be expected, the total
1O2 luminescence
increased with radiant exposure (fluence) at a constant irradiance.
Figure 5 (inset) shows the skin scores for spots treated with
50Jcm
 2 at varying irradiances, corresponding to the treatments
in Figure 3, as well as the unsensitised controls at 50mWcm
 2.
The unsensitised animals had no observable response to light
alone at 15 or 150mWcm
 2 or to ALA alone (data not shown for
brevity). For the sensitised animals, the skin response increased
significantly with decreasing irradiance. This was statistically
significant: P¼0.001 between 15 and 50mWcm
 2 and P¼0.003
between 50 and 150mWcm
 2. This irradiance dependence was
also observed by Robinson et al (1998), and similar effects have
been reported by other authors in different in vitro and in vivo
models (Feins et al, 1990; Gibson et al, 1990; Foster et al, 1993;
Sitnik et al, 1998), and has usually been attributed to photo-
chemical depletion of oxygen at high irradiances. The total skin
scores as a function of fluence for all treatments are summarised in
Figure 5. These were defined as the sum of the 14 individual daily
scores over the 2-week period in each case. Again, these are
generally consistent with those obtained by Robinson et al (1998).
A striking feature in Figures 3–5 is the relatively large variability
in the measurements for nominally identical PDT treatments. As
will be discussed, this variability was primarily due to animal-to-
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Figure 2 Typical NIR spectra measured from single sensitised,
unsensitised and hypoxic animals. For the sensitised animal, the individual
spectra were measured at different times during treatment. For the control
and hypoxic animals, error bars reflect the standard deviation of four
spectra acquired for the same animal.
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Figure 3 Cumulative
1O2 luminescence in sensitised animals irradiated
to 50Jcm
 2 at 15, 50 or 150mWcm
 2. Each point represents the mean
for six animals, 71s.d. The lines are simply to guide the eye and typical
error bars are shown.
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Figure 4 Total
1O2 luminescence as a function of total fluence for all
treatment groups (means71s.d. in six animals).
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sanimal differences in ALA uptake and/or PpIX synthesis, local skin
pO2 and relative photosensitivity of the skin, as opposed to true
‘experimental error’. The variability observed here was not
atypically large, but serves to illustrate the difficulty inherent in
predicting the outcome of PDT treatments based on administered
light and photosensitiser dose alone.
The total skin score as a function of the total
1O2 luminescence
for all treatments is shown in Figure 6. There is a strong
correlation with the
1O2 luminescence, regardless of the fluence or
irradiance used. Figure 7 shows the individual data points that
comprise Figure 6, together with the best w
2 fit to a three-
parameter sigmoidal curve (constrained to pass through the
origin) of the form:
TSSðLÞ¼
A
1 þ 10 B½logðLÞ logðCÞ  ðEÞ
where TSS is the total skin score and L is the total
1O2
luminescence measured. The use of this functional form for the
response has no a priori mechanistic basis at this time, but is a
convenient way to summarise the data. This fit was performed with
four outliers removed (dotted symbols in Figure 7) and this fit
yielded A¼71, B¼1.6 and C¼108000 and a reduced w
2 of 2.0 (w
2/
NDF¼5.1 with all data points included).
DISCUSSION
Technical issues
As with our previous work (Patterson et al, 1990; Niedre et al,
2002a,b; Niedre et al, 2003), we chose to use a set of NIR band-pass
filters for spectral discrimination of the detected light rather than a
monochromator (Hirano et al, 2002), since it allowed for
maximum optical throughput and minimised the distance between
the source and detector. Furthermore, after we verified that our
system was capable of measuring
1O2 luminescence in this in vivo
model, we were able to use a set of only three filters, since the
1270nm peak was unambiguous.
The addition of a small, 4 4mm prism in front of the
collection optics allowed close positioning of the animals while
allowing irradiation of the treatment spot. Since less than 1% of the
field of view of the detector was blocked by this prism, the impact
on signal collection was minimal.
Accurate positioning of the skin spot during
1O2 luminescence
measurements was important, since different animals were
measured over an extended period of time and absolute
1O2
luminescence measurements were compared. The pair of align-
ment lasers ensured that the animals were positioned reproducibly
with an accuracy (height) of about 70.5mm at the focal plane of
the detection system, so that the complete system response was
consistent. Furthermore, the laser irradiance, measured before
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Figure 5 Total skin score (means71s.d. in six animals) as a function of
total fluence for all treatment conditions. Inset: skin score as a function of
time following treatment in days (means71s.d. in six animals).
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Figure 6 Total skin score (means71s.d.) as a function of total
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Figure 7 Total skin score as a function of total
1O2 luminescence for all
individual data points that comprise the figure. The curve is the fit to
Equation (E) after removal of the four outliers (open points). The error
bars indicate the assumed systematic uncertainty in the visual scoring, taken
as 70.5 units on each score.
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seach treatment was stable to 75% RMS, while the power supply
for the PMT was stable to 71V.
Singlet oxygen as an in vivo dose metric
The key finding in this study is that treatment response in normal
mouse skin in vivo correlates strongly
1O2 luminescence measured
during PDT. Furthermore, this was the case even for a range of
radiant exposures and irradiances over which the response showed
significant variation. In addition, as discussed earlier, significant
variability was observed in both
1O2 luminescence and skin
response for nominally identical treatments. The fact that the
points from the individual experiments follow a single (sigmoidal)
curve (Figure 7) illustrates the ability of this technique to account
for variability in treatment factors such as PpIX concentration and
skin pO2. Although significantly more scatter (and outlying data
points) from the parent curve is evident in Figure 7 than in our
analogous in vitro studies (Niedre et al, 2003), this was not
unexpected, since more variability should exist in the photo-
biological response between individual mice than between sets of
cells from clonal populations. Also, the skin scoring system used in
these experiments is somewhat subjective and may have con-
tributed to this scatter.
The fraction of
1O2 that undergoes radiative decay relative to all
1O2 generated in the treatment volume (regardless of de-excitation
pathway) is given by the ratio of the
1O2 lifetime to the
luminescence lifetime, that is, tD/tL (Lamola, 1971). Hence,
although the probability of radiative decay is extremely low in
vivo (Niedre et al, 2002b), the emitted luminescence is tightly
coupled to the ‘active’, nonradiating fraction of
1O2. The fact that
the
1O2 luminescence measured here correlates extremely well with
the treatment response further demonstrates this relationship. In
addition, the
1O2 luminescence signal was undoubtedly hetero-
geneous in origin in that, for example, the photosensitiser was
likely concentrated in specific tissue and/or cellular compartments
(e.g. mitochondrial membrane; Wilson et al, 1997b) and the
oxygenation is higher in membranes than in cytosol. However, the
proportion of radiative vs nonradiative
1O2 was consistent between
experiments, since we used the same photosensitiser and
application conditions in all cases. This might be a complicating
factor if, for example,
1O2 luminescence was compared to
treatment response using different photosensitisers and adminis-
tration conditions. Moreover, the effect of tissue optics in these
experiments was minimal, since we deliberately chose a relatively
homogeneous tissue model as opposed to, for example, a murine
tumour model (Robinson et al, 1998).
This work, together along with our earlier dose–response
studies in cells, supports the generally-held hypothesis that
1O2 is
the important cytotoxin involved in PDT. Furthermore, since the
relationship between
1O2 generation and treatment response holds
in vivo, this work further demonstrates the utility of using
1O2
luminescence as a PDT dosimetry tool. However, the possibility
that
1O2 is only one of the ROS generated cannot be discounted,
nor can the possibility that other ROS are more important for
different photosensitisers.
Irradiance effects
Strong irradiance effects were observed in these experiments, both
in terms of
1O2 luminescence generation and treatment response.
Irradiance effects have been observed by other authors (Feins et al,
1990; Gibson et al, 1990; Foster et al, 1993; Robinson et al, 1998;
Sitnik et al, 1998) and have usually been attributed to rapid
photochemical depletion of molecular oxygen at higher irra-
diances. The
1O2 luminescence measurements here appear to be
consistent with this interpretation. Specifically, Figure 8 shows the
cumulative
1O2 luminescence (as in Figure 3) as a function of total
treatment time. The fact that all of the curves appear to reach
approximately the same terminal slope regardless of irradiance
implies that
1O2 generation was not limited by the number of
excitation photons in each laser pulse, but rather by the available
molecular oxygen and/or photosensitiser ground state. We are
currently investigating both of these possibilities in more detail.
Other observations
Robinson et al (1998) observed rapid photobleaching of the
photosensitiser: for example, greater than 90% of the PpIX was
bleached after 10Jcm
 2 at their lowest irradiance. This appears to
contradict our data, since the incremental
1O2 generation at
15mWcm
 2 appeared unaffected by the bleaching of the
photosensitiser and decreased only slightly at later time points
(Figure 8). A possible explanation for this is the formation of
photosensitive photoproducts during PpIX irradiation (Finlay et al,
2001). These photoproducts are known to absorb at 523nm and
therefore may have acted as secondary photosensitisers, allowing
sustained photodynamic generation of
1O2. Alternatively, it is
possible that sufficient PpIX was always present during treatment,
so that the concentration of molecular oxygen was the limiting
factor in
1O2 generation even after several orders of magnitude of
photosensitiser photobleaching. This further illustrates the poten-
tial value of
1O2 luminescence-based dosimetry, since complicating
factors such as photobleaching, formation of photosensitive
photoproducts and tissue oxygenation are all implicitly incorpo-
rated into a single measurement.
Analysis of the data of Figure 7 showed that the lowest
1O2
luminescence counts measured from any treatment that resulted in
an individual skin response score of 5 or higher (i.e. scab
formation/necrosis) at any day post-treatment was 61000 photon
counts. Given the system geometric collection efficiency (0.02),
quantum efficiency of the detector (0.01), optical throughput of the
collection optics (0.2) and the probability of radiative decay of
1O2
in tissue (¼tD/tLB100ns/5.55s B2 10
 8) (Niedre et al, 2002b),
this was equivalent to B7 10
16 molecules of
1O2 in the treatment
volume. Assuming a typical cell density in tissue of around
10
9cm
 3 and, given that the effective treatment volume was
approximately 0.5cm
2 with a depth of 25mm (Robinson et al,
1998), the
1O2 necrosis threshold for this model was about
5.8 10
10 molecules of
1O2 per cell. This is can be compared to
Georgakoudi et al’s (1997) estimate of B7 10
9 molecules of
1O2
per cell in EMT6 spheroids treated with Photofrin-PDT, and Farrel
0 10 20 30 40 50 60
Total treatment time (min)
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
15 mW cm−2
50 mW cm−2
150 mW cm−2
× 105
C
u
m
u
l
a
t
i
v
e
 
1
O
2
 
c
o
u
n
t
s
Figure 8 Total
1O2 luminescence vs total treatment time for animals
that received 50Jcm
 2 at 15, 50 or 150mWcm
 2 (means71s.d.).
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set al’s (1991) estimate of B5 10
8 per cell in rat liver treated with
Photofrin-PDT, Interestingly, it is also significantly higher than
our own estimate of the 5.6 10
7 molecules
1O2 per cell to achieve
1/e cell death in OCI-AML5 cells in vitro with ALA-PpIX (Niedre
et al, 2003). This apparently higher threshold for the skin response
likely reflects the relative insensitivity of normal mouse epidermal
cells vs leukaemia cells, and the lack of a vascular component in
the treatment response to ALA-PpIX PDT vs that of Photofrin-
PDT. It should also be noted that this result is sensitive to the
assumed treatment depth; here, we have assumed that PpIX
synthesis is confined to the epidermis as described by Kennedy
and Pottier (1992) and Robinson et al (1998), but there may have
been contributions from the dermis as well. This would lead to the
above threshold value being overestimated.
CONCLUSIONS
In summary, this work demonstrates the potential value of
1O2
luminescence as a dose metric in vivo. Combined with our
previous studies, the prospect of further extending this work
towards a clinical dosimetry system is encouraging. We plan to
repeat these studies next in an implanted tumour model that has
an increased level of complexity due to inherent heterogeneity in
optical properties, photosensitiser uptake and oxygenation. This
may require further modification of the system to provide spatial
information as well as single, volume-averaged
1O2 luminescence
measurements. If successful, we then plan to perform a clinical
demonstration of
1O2 luminescence measurements during PDT,
probably initially on skin cancer patients.
ACKNOWLEDGEMENTS
This work was supported by the Canadian Cancer Society under
a grant from the National Cancer Institute of Canada. We also
thank Hamamatsu Corp., Hamamatsu City, Japan, and in
particular Dr Ken Kaufmann (Hamamatsu, Bridgewater, NJ,
USA), for supporting the acquisition of the PMT system, and the
Canadian Foundation for Innovation and the Princess Margaret
Hospital Foundation for equipment support. The assistance
of Anoja Giles, Sandra Lafranc, and Dr Kai Zhang is also grate-
fully acknowledged. Dr Tom Foster provided invaluable advice
on the interpretation of the above results, for which we are most
grateful.
REFERENCES
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M,
Moan J, Peng Q (1998) Review: photodynamic therapy. J Natl Cancer Inst
90: 889–905
Dysart JS, Patterson MS, Farrell TJ, Singh G (2002) Relationship between
mTHPC fluorescence photobleaching and cell viability during in vitro
photodynamic treatment of DP16 cells. Photochem Photobiol 75:
289–295
Farrel TJ, Wilson BC, Patterson MS, Chow R (1991) The dependence of
photodynamic threshold dose on treatment parameters in normal rat
liver in vivo. Proc SPIE 1426: 146–155
Feins RH, Hilf R, Ross H, Gibson SL (1990) Photodynamic therapy for
human malignant mesothelioma in the nude mouse. J Surg Res 49:
311–314
Finlay JC, Conover DL, Hull EL, Foster TH (2001) Porphyrin bleaching and
PDT-induced spectral changes are irradiance dependent in ALA-
sensitized normal rat skin in vivo. Photochem Photobiol 73: 53–63
Foster TH, Hartley DF, Nichols MG, Hilf R (1993) Fluence rate effects in
photodynamic therapy of multicell tumor spheroids. Cancer Res 53:
1249–1254
Georgakoudi I, Nichols MG, Foster TH (1997) The mechanism of photofrin
photobleaching and its consequences for photodynamic dosimetry.
Photochem Photobiol 65: 135–144
Gibson SL, VanDerMeid KR, Murant RS, Raubertas RF, Hilf R (1990)
Effects of various photoradiation regimens on the antitumor efficacy of
photodynamic therapy for R3230AC mammary carcinomas. Cancer Res
50: 7236–7241
Gorman AA, Rodgers MAJ (1992) Current perspectives of singlet oxygen
detection in biological environments. J Photochem Photobiol B 14:
159–176
Hirano T, Kohno E, Nishiwaki M (2002) Detection of near infrared
emission from singlet oxygen in PDT with an experimental tumor
bearing mouse. J Jpn Soc Laser Surg Med 22: 99–108, (in Japanese)
Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically
useful photosensitizer for photodynamic therapy. J Photochem Photobiol
B 14: 275–292
Krasnovsky AA (1998) Singlet molecular oxygen in photobio-
chemical systems: IR luminescence studies. Membrane Cell Biol 12:
665–690
Lamola AA (1971) Creation and Detection of the Excited State. New York:
Marcel Dekker Inc
Moan J, Berg K (1991) The photodegradation of porphyrins in cell can be
used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:
549–553
Niedre MJ, Patterson MS, Boruvka N, Wilson BC (2002a) Measurement of
singlet oxygen luminescence from AML5 cells sensitized with ALA-
induced PpIX in suspension during photodynamic therapy and
correlation with cell viability after treatment. Proc SPIE 4612: 93–101
Niedre M, Patterson MS, Wilson BC (2002b) Direct near-infrared lumine-
scence detection of singlet oxygen generated by photodynamic therapy in
cells in vitro and tissues in vivo. Photochem Photobiol 75: 382–391
Niedre MJ, Secord AJ, Patterson MS, Wilson BC (2003) In vitro tests of the
validity of singlet oxygen luminescence measurements as a dose metric
in photodynamic therapy. Cancer Res 63: 7986–7994
Parker JG (1987) Optical monitoring of singlet oxygen during photo-
dynamic treatment of tumors. IEEE Circ Devices Mag 3: 10–21
Patterson MS, Madsen SJ, Wilson BC (1990) Experimental tests of singlet
oxygen luminescence monitoring in vivo during photodynamic therapy.
J Photochem Photobiol B 5: 69–84
Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star
WM (1998) Fluorescence photobleaching of ALA-induced protoporphyr-
in IX during photodynamic therapy of normal hairless mouse skin: the
effect of light dose and irradiance and the resulting biological effect.
Photochem Photobiol 67: 140–149
Schweitzer C, Schmidt R (2003) Physical mechanisms of generation and
deactivation of singlet oxygen. Chem Rev 103: 1685–1757
Sitnik TM, Hampton JA, Henderson BW (1998) Reduction of tumor
oxygenation before and after photodynamic therapy in vivo: effects of
fluence rate. Br J Cancer 77: 1386–1394
Stewart F, Baas P, Star W (1998) What does photodynamic therapy have to
offer radiation oncologists (or their cancer patients)? Radiother Oncol 48:
233–248
Weishaupt KR, Gomer CJ, Dougherty TJ (1976) Identification of singlet
oxygen as the cytotoxic agent in photo-inactivation of a murine tumor.
Cancer Res 36: 2326–2392
Wilson BC, Olivo M, Singh G (1997b) Subcellular localization of Photofrin
and aminolevulinic acid and photodynamic cross-resistance in vitro in
radiation-induced fibrosarcoma cells sensitive or resistant to Photofrin-
mediated photodynamic therapy. Photochem Photobiol 65: 166–176
Wilson BC, Patterson MS, Lilge L (1997a) Implicit and explicit dosimetry in
photodynamic therapy: a new paradigm. Lasers Med Sci 12: 182–199
1O2 luminescence in photodynamic therapy in vivo
MJ Niedre et al
304
British Journal of Cancer (2005) 92(2), 298–304 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s